cervical%20cancer%20-%20treatment
CERVICAL CANCER - TREATMENT
Patients w/ abnormal Pap smear are referred for colonoscopy to screen for presence of cervical cancer.
Colposcopic exam should include inspection of the transformation zone, definition of the extent of the lesion & biopsy of the most abnormal area for tissue diagnosis.
The earliest stages of cervical carcinoma are generally asymptomatic.
Watery vaginal discharge & postcoital bleeding or intermittent spotting may be present & are usually unrecognized by the patient.

Cervical Cancer - Treatment Drug Information

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Primary treatment of ovarian cancer in combination w/ platinum agent. Metastatic ovarian or breast cancer, aft...

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Advanced stage ovarian cancer of epithelial origin.

Indication: Advanced ovarian carcinoma of epithelial origin.

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Locally advanced or metastatic non-small cell lung cancer (NSCLC) & pancreatic adenocarcinoma, 5-FU refrac...

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 21 Oct 2020

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.